spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Eprodisate 

 HSMN NewsFeed - 13 Mar 2008
Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2007
Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Nov 2007
Neurochem announces important initiatives to provide medical and health benefits to patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Aug 2007
Neurochem provides information on cash position
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Jul 2007
Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 17 Jul 2007
Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jun 2007
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Jun 2007
Neurochem receives third recommendation from European Data Safety Monitoring Board to continue Phase III clinical trial for tramiprosate (ALZHEMED(TM))
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 7 Jun 2007
Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA(TM)) Treatment for Patients with Amyloid A (AA) Amyloidosis
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2007
Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Feb 2007
Neurochem receives second recommendation from European Data Safety Monitoring Board to continue Phase III clinical trial for tramiprosate (ALZHEMED(TM))
Biopharmaceuticals Neurology
 HSMN NewsFeed - 1 Feb 2007
Neurochem announcement regarding the completion of its North American phase III clinical trial for tramiprosate (ALZHEMED(TM)) for the treatment of Alzheimer's disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Nov 2006
Neurochem receives recommendations from data safety monitoring boards to continue phase III clinical trials for tramiprosate (ALZHEMED(TM))
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Nov 2006
Tramiprosate (ALZHEMED(TM)) Phase II Clinical Results Published in Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Oct 2006
Neurochem submits a complete response to FDA approvable letter for KIACTA(TM)
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 2 additional stories matching:
Eprodisate
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.